Multiple Sclerosis Diagnosis: From Oligoclonal Bands to New Biomarkers — A Patient's Guide to How MS Is Diagnosed and Monitored

Table of Contents

• Key Points
• Understanding Multiple Sclerosis
• Why an Accurate and Early MS Diagnosis Is So Difficult
• The Critical Role of Cerebrospinal Fluid Analysis
• Oligoclonal Bands: The Current "Gold Standard" Test
• Mathematical Formulas for Measuring Antibody Production
• Kappa Free Light Chains: A New Biomarker for MS
• Why Kappa Free Light Chains May Be Better Than Lambda
• κFLC and Predicting Early Disease Activity
• The Numbers: How Accurate Are These Tests?
• Clinical Implications: What This Means for You
• Study Limitations: What This Review Couldn't Prove
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• MS diagnosis integrates neurological examination, MRI, and cerebrospinal fluid analysis using the 2017 McDonald criteria; no single test confirms the disease.
• Oligoclonal band detection by isoelectric focusing is the gold standard, found in about 95% of confirmed MS patients, but it is qualitative and can be positive in other conditions.
• In a recent meta-analysis, the kappa free light chain index had weighted average sensitivity of 88% and specificity of 89%, comparable to oligoclonal bands.
• Higher intrathecal kappa free light chain synthesis at a first episode may predict greater risk of converting to clinically definite MS.
• IgM oligoclonal bands and an elevated IgM index have been linked to increased risk of disease progression and poorer prognosis.

Understanding Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, and disabling disorder that affects the central nervous system (the brain and spinal cord). The disease is characterized by three processes happening simultaneously: demyelination (damage to the protective myelin sheath that surrounds nerve fibers), neurodegeneration (progressive loss of nerve cells), and ongoing inflammation in the central nervous system.

According to the latest Multiple Sclerosis Atlas, an international data-collection project, about 2.8 million people have MS worldwide. That number has been rising over the last decade. Researchers attribute this increase to several factors: people are living longer, the global population is growing, data collection has improved, and diagnostic techniques are better than they used to be.

MS prevalence varies widely by geographical region and population. It also differs by sex and age.

Most MS patients first experience what doctors call a clinically isolated syndrome (CIS). A CIS is defined as a single episode of demyelination affecting the central nervous system, lasting at least 24 hours, that cannot be explained by other diseases such as infections or metabolic disorders. Although the course of MS varies greatly from person to person, most patients first have symptoms with complete or partial recovery, followed by periods of stability or remission. This condition often evolves into relapsing-remitting MS (RRMS), the most common form. About one in four patients (roughly 25%) eventually advance to a progressive form of MS (PMS) after a long phase of disease evolution.

The root cause of MS is an alteration in the immune system. In particular, researchers have identified defects in regulatory T cells (Treg cells), which normally help keep the immune response in check. The exact cause of MS is still debated, but recent findings point to a combination of factors:

• Genetic predisposition: several human leukocyte antigen (HLA) risk alleles (gene variants), as well as variants of the interleukin-2 receptor alpha gene (IL2RA) and the interleukin-7 receptor alpha gene (IL7RA), are likely involved.
• Infections: some studies suggest certain viral or bacterial antigens, or superantigens, may trigger MS through molecular mimicry (when foreign molecules resemble the body's own proteins, causing the immune system to attack itself).
• Environmental factors: smoking, obesity, and low sun exposure (leading to low serum vitamin D) have all been hypothesized to increase susceptibility to MS.

Why an Accurate and Early MS Diagnosis Is So Difficult

Making a correct MS diagnosis remains a significant challenge. The difficulty stems from the fact that many central nervous system diseases share similar nonspecific symptoms with MS. Conditions that can look like MS include migraines, fibromyalgia, abnormal MRI findings, functional neurological disorder, and neuromyelitis optica (a different autoimmune disease that affects the optic nerves and spinal cord).

Currently, doctors rely most widely on the McDonald criteria, which were revised in 2017. According to these criteria, doctors must prove that there is damage to the central nervous system, that plaques (lesions) exist in multiple regions of the nervous system, and/or that the damage has spread over time—meaning lesions occur at different points in the patient's life. Importantly, the presence of oligoclonal bands in the cerebrospinal fluid can replace the requirement for demonstrating spread over time. In other words, a single spinal tap result can sometimes substitute for waiting to see if new lesions develop.

Early treatment can delay long-term disease progression and improve outcomes, as measured by the expanded disability status scale (EDSS), a standard tool that grades disability in MS patients. This makes an accurate diagnosis especially urgent for patients with CIS who are at high risk of developing relapsing-remitting or progressive MS.

The Critical Role of Cerebrospinal Fluid Analysis

The most used laboratory test for MS examines the cerebrospinal fluid (CSF)—the clear fluid that surrounds the brain and spinal cord—for signs of antibody production within the central nervous system. Because no single clinical feature or diagnostic blood test can identify MS with certainty, current diagnosis integrates clinical findings, MRI results, and laboratory analysis of the CSF.

When the immune system is active inside the brain and spinal cord, it produces antibodies (immunoglobulins) locally. This process is called intrathecal synthesis, meaning antibody production within the theca (the protective sheath around the brain and spinal cord). Detecting this local antibody production is the cornerstone of laboratory-supported MS diagnosis.

Oligoclonal Bands: The Current "Gold Standard" Test

Interest in the protein bands now called oligoclonal bands dates back to the middle of the last century, when a study reported that 80% of MS patients had elevated gamma globulins (a type of immune protein) in their cerebrospinal fluid. That finding was confirmed by later studies. As laboratory techniques improved, researchers were able to see specific bands with IgG properties (a class of antibodies) in the gamma globulin zone of MS patients' CSF that were absent in the same patients' blood serum.

Doctors observed a positive correlation between IgG levels in the demyelinating plaques and in the cerebrospinal fluid of MS patients. This led to the hypothesis that IgG is synthesized locally in the brains of MS patients. Those specific bands became known as oligoclonal bands (OCBs)—"oligo" meaning few, and "clonal" meaning derived from a small number of immune cell clones.

Today, the standard technique for detecting OCBs is isoelectric focusing (IEF), a laboratory method that separates proteins based on their electrical charge, followed by immunoblotting or immunofixation (detection methods that use antibodies to identify the separated proteins). This combined approach is considered the "gold standard" for revealing increased IgG production inside the central nervous system.

The assay detects OCBs in about 95% of patients with confirmed MS. When OCBs appear in the CSF of a patient who has had a clinically isolated syndrome (a first episode), their presence is a prognostic factor—meaning it predicts a higher chance that the patient will convert to full MS. However, OCBs can also appear in other chronic inflammatory diseases of the central nervous system.

The OCB detection technique involves running paired CSF and serum samples side by side. The interpretation of results is somewhat subjective and can be visualized as five typical patterns of OCBs in CSF and serum. Intrathecal OCB synthesis is defined as one of two things:

• Bands present in the CSF only (not in the blood serum), or
• Bands present in both serum and CSF, but with additional bands present in the CSF sample

Standardization of the IEF method is difficult. It is a multi-step, complex procedure with several variables that can influence the results. It is also expensive and time-consuming.

The test has reported sensitivity and specificity of approximately 90%. But it has important drawbacks: it only provides a qualitative analysis (is IgG synthesis happening or not?) rather than a quantitative one (how much synthesis is happening?). It is also technically demanding, labor-intensive, costly, and dependent on the examiner's subjective interpretation.

It is also important to note that intrathecal positivity of immunoglobulins can occur in central nervous system diseases other than MS. Examples include:

• Optic neuritis (inflammation of the optic nerve)
• Autoimmune encephalitis (brain inflammation caused by the immune system)
• Neurosarcoidosis (a condition causing inflammatory lumps in the nervous system)
• Neuromyelitis optica (NMO)
• Anti-MOG antibody disease (a disorder caused by antibodies against myelin oligodendrocyte glycoprotein)

These conditions can produce intrathecal antibodies through several mechanisms, including altered permeability of the blood–brain barrier (BBB), local antibody production, or a combination of both. During inflammatory processes, cells from the bloodstream can cross the blood–brain barrier into the central nervous system and produce immunoglobulins there. This is why OCB results must always be evaluated alongside the clinical picture to provide a proper MS diagnosis.

Mathematical Formulas for Measuring Antibody Production

Because the OCB test is only qualitative, doctors have developed mathematical formulas to estimate how much immunoglobulin is actually being produced inside the central nervous system. These formulas adjust for the amount of antibody that leaks in from the blood through a damaged blood–brain barrier.

The simplest and most widely used formula is the IgG index. This index compares the amount of IgG to albumin in the CSF, relative to the same ratio in serum. Albumin is not synthesized in the central nervous system, so its presence in CSF comes exclusively from the blood. The CSF albumin concentration is about 200 times lower than in serum. IgG also migrates from serum to CSF, at an average concentration about 500 times lower in CSF than in serum (normal serum ranges are 37–54 g/L for albumin and 7.0–14.0 g/L for IgG). By using the albumin quotient, the formula accounts for the degree of blood–brain barrier dysfunction.

The IgG index has a key limitation: low sensitivity. Although nearly 70% of MS patients show an increased IgG index, other central nervous system diseases can also display an elevated index. However, the method does benefit from the fact that the needed measurements (IgG and albumin concentrations) are routinely collected during CSF analysis anyway.

The Reiber formula takes a more sophisticated approach. It considers the relationship between CSF and serum concentration quotients for three classes of immunoglobulins—IgG, IgA, and IgM—and the albumin ratio, in a nonlinear manner that accounts for progressively worsening blood–brain barrier damage. In the presence of such damage, the Reiber formula produces fewer false-positive results than the IgG index.

A more recently proposed approximation, called Auer's formula, is also likely to generate few false-positive results, especially for IgM and IgA. However, IgM and IgA detection has limited practical use in routine CSF analysis.

One recent retrospective study directly compared these approaches. Researchers applied the linear IgG index, Auer's formula, and the hyperbolic Reiber function to a cohort of 372 patients with central nervous system demyelination to evaluate how well each method detected intrathecal IgG synthesis. The results were striking:

• Auer's method showed high specificity (95%) but very low sensitivity (68%)
• The Reiber formula's sensitivity was 83%
• The IgG index had the highest sensitivity at 89%

The authors concluded that the hyperbolic Reiber function was overall superior when balancing sensitivity and specificity.

The review also notes that IgM oligoclonal bands can be detected as evidence of intrathecal IgM production. Their presence has been linked to an increased risk of disease progression. Likewise, the IgM index—calculated using the same formula as the IgG index—predicts a poorer disease prognosis.

Kappa Free Light Chains: A New Biomarker for MS

Since the 1980s, researchers have been developing and testing alternative biomarkers that could complement or even replace the OCB test. The most promising candidate is the kappa free light chain (κFLC).

To understand κFLCs, a quick biology lesson helps. When B lymphocytes (the immune cells that produce antibodies) make immunoglobulins, they create both heavy chains and light chains. Normally, these chains bind together to form a complete, intact immunoglobulin molecule. But B cells also produce an excess of free light chains—light chains that are not attached to heavy chains—and secrete these into the bloodstream. Free light chains exist in two types: kappa (κ) and lambda (λ). Kappa FLCs mostly exist as single units (monomers), while lambda FLCs form pairs (covalent dimers).

Free light chains were first identified in 1847 and are known as Bence Jones proteins, a name that remains familiar in clinical laboratory diagnostics. In 1980, researchers first measured kappa free light chain concentration in the serum and CSF of MS patients using an assay called nephelometry (a technique that measures light scattered by particles in a liquid). That method was later automated and, along with turbidimetry (a similar light-based technique) and ELISA (enzyme-linked immunosorbent assay), remains among the most widely used approaches today.

Several studies have compared these techniques. They found essentially similar results in terms of diagnostic sensitivity and specificity. However, one ELISA approach based on monoclonal antibodies against cryptic (hidden) epitopes of free light chains outperformed the nephelometric assay. Other methods, such as affinity-mediated immunoblotting after isoelectric focusing, have also been tested and proposed as useful alternatives.

A crucial technical milestone was the development of antibodies that specifically recognize free light chains without cross-reacting with the light chains still attached to complete immunoglobulins. These antibodies target epitopes (the parts of a molecule that antibodies bind to) that are hidden in intact immunoglobulins but exposed in free light chains. This solved a long-standing problem that had limited the use of FLC testing.

Why Kappa Free Light Chains May Be Better Than Lambda

Researchers generally agree that both κFLC and λFLC levels increase in the CSF of MS patients compared with patients who have non-inflammatory neurological diseases. But the increase in λFLCs is less pronounced than the increase in κFLCs. That difference matters clinically.

One previous study found that MS patients had higher κFLC levels than patients with central nervous system infectious diseases, but similar λFLC levels. This suggests that elevated λFLC might actually be a marker of infection rather than a marker specific to MS.

Even more recent work could not produce reliable data for the lambda index because λFLC levels were often below the detection limit of the assays. This meant the lambda index could not constitute a valid test for CIS/MS diagnosis. Taken together, these findings indicate that κFLCs show better diagnostic performance in MS, and the κFLC index has higher sensitivity and specificity than its lambda counterpart.

That said, studies using absolute κFLC concentrations have reported high diagnostic accuracy but with considerable variability in the cutoff values. This variability stems from two sources: the different technologies used across laboratories, and the different patient populations studied (many studies used small sample sizes and heterogeneous groups, such as control groups that included patients with inflammatory neurological diseases).

κFLC and Predicting Early Disease Activity

The earliest studies measuring κFLCs for MS diagnosis did not account for the integrity of the blood–brain barrier or for individual variations in immunoglobulin concentrations. This oversight generated both false-positive and false-negative results. Just as with IgG, it is essential to determine how much κFLC is actually being produced locally in the central nervous system, rather than simply measuring the total amount in the spinal fluid.

In recent years, the most common approach has therefore become the calculation of the κFLC index. This index is the ratio between CSF and serum κFLC levels, adjusted for blood–brain barrier permeability through the CSF/serum albumin quotient (QAlb). The formula is:

κFLC index = (κFLC in CSF ÷ κFLC in serum) ÷ QAlb

Each component is measured in the same units, and the QAlb corrects for the amount of protein that leaks from blood into CSF. This adjustment matters because the contribution of blood-derived FLCs to the total CSF concentration is usually very small—in fact, the intrathecal (locally produced) κFLC fraction is greater than 80% in most MS patients. But in patients with only low or moderate intrathecal κFLC production, blood levels and blood–brain barrier function can significantly distort the result. Elevated serum FLC levels or a high degree of blood–brain barrier dysfunction are now recognized as confounders (factors that can mislead interpretation).

One study powerfully illustrated this point: researchers found different κFLC index values between patients who converted to MS and those who did not, even though the absolute CSF κFLC concentrations were similar between the two groups. This finding highlights the practical importance of calculating the κFLC index rather than relying on a raw concentration number.

Several additional algorithms have been proposed and are being investigated to refine the measurement of intrathecal κFLC synthesis. These methods calculate the intrathecal κFLC fraction using different formulas that define an upper reference limit depending on QAlb. Among them, the most recommended is the Reiber diagram, a graphical method favored because it is based on the underlying physiology, is less influenced by pre-analytical factors (errors that can occur before the actual test run), and shows outstanding accuracy.

The Numbers: How Accurate Are These Tests?

Both the OCB test and the κFLC index have been studied extensively. A very recent meta-analysis (a statistical study that pools results from many separate studies) provides the clearest picture yet.

For the κFLC index, diagnostic sensitivity ranges from 52% to 100%, with a weighted average of 88%. Specificity ranges from 69% to 100%, with a weighted average of 89%. For context, sensitivity means the test correctly identifies people who have the disease, while specificity means the test correctly rules out people who do not have it.

For OCBs, the same meta-analysis found sensitivity ranging from 37% to 100% (weighted average 85%) and specificity from 74% to 100% (weighted average 92%). The mean difference in diagnostic sensitivity between the κFLC index and OCBs was +2 percentage points (favoring κFLC), and the mean difference in specificity was −4 percentage points (favoring OCB). No difference was observed for overall diagnostic accuracy.

To put it in simple terms with absolute numbers: imagine 100 people with MS and 100 healthy controls. Using average performance figures, the κFLC index would correctly identify about 88 of the 100 MS patients and correctly classify about 89 of the 100 controls. The OCB test would correctly identify about 85 MS patients and correctly classify about 92 controls. These are comparable performances, with each test having small advantages in different directions.

The wide range of values observed for both tests comes primarily from differences in the patient groups between studies. The ranges narrow considerably when inflammatory neurological disease patients are excluded from control groups.

For CSF κFLC concentration used as a standalone measurement, cutoff values varied dramatically between studies, from 0.103 µg/mL all the way to 7 mg/L. The mean diagnostic sensitivity was 86% (95% confidence interval: 80% to 92%) and specificity was 91% (95% confidence interval: 86% to 96%).

Clinical Implications: What This Means for You

If you or a loved one is undergoing evaluation for MS, these findings have several practical implications.

First, the tests are not perfect—and that's expected. A negative OCB result does not exclude MS, and a positive result does not by itself confirm it. The review authors stress that OCB detection should be evaluated together with the clinical picture and other disease features.

Second, the κFLC test offers real advantages. It is quantitative (it produces a number, not just a yes/no answer), it can be automated, and it is less dependent on the examiner's subjective interpretation than the OCB test. Studies have repeatedly shown that the κFLC index achieves diagnostic accuracy that is similar to or better than OCB detection. This means that some patients who show signs of a demyelinating event but do not have clear IgG bands might still be diagnosed earlier through κFLC testing.

Third, κFLC may help predict disease activity. Recent studies highlighted in this review indicate that the κFLC index has value not only for diagnosis but also for predicting early disease activity—essentially, how likely the disease is to become active and progress after a first episode. Patients with higher intrathecal κFLC synthesis at the time of their CIS may be at greater risk of converting to clinically definite MS.

Fourth, monitoring matters. Because there is no definitive cure for MS, treatment focuses on managing acute attacks, reducing symptoms, and controlling biological activity through disease-modifying therapies. These treatments can improve disability-free life expectancy. Many physicians now advise using these therapies early, before permanent disability becomes evident. But the balance of benefits versus risks of particular therapies varies greatly between individuals. Having biomarkers that can help predict which patients will have a more aggressive course helps doctors decide whether to start treatment, which treatment to choose, and how soon to begin.

Study Limitations: What This Review Couldn't Prove

This article is a review of existing published research, not a single new clinical study. As such, it inherits the limitations of the studies it summarizes. Several limitations deserve emphasis:

• Study heterogeneity: The wide ranges of sensitivity and specificity for both OCBs and the κFLC index stem largely from differences between study populations. Some studies included patients with other inflammatory neurological diseases in their control groups, which lowers apparent specificity. Sample sizes in many studies were small.
• Technical variability: There is no universally standardized method for measuring κFLC. Different assays (nephelometry, turbidimetry, ELISA) and different instruments produce somewhat different results. The review authors advise that, although various automated nephelometric assays perform comparably, the same assay should preferably be used throughout an individual patient's follow-up.
• Best formula not yet settled: A better approach to measuring intrathecal κFLC synthesis still needs to be established. Studies have variously used absolute CSF κFLC concentration, the κFLC quotient (Q-κFLC), the κFLC index, or more complex algorithms. The Reiber diagram is currently the most recommended but is not universally adopted.
• No single test confirms MS: OCB detection through IEF is not disease-specific. Other neuroinflammatory diseases can produce positive results, and a positive OCB result must always be interpreted in the full clinical context.
• Missing long-term outcome data: While κFLC shows clear diagnostic value, its exact role in predicting long-term disability and in monitoring therapeutic response is still being defined. The review states that these applications are areas of active investigation.

Recommendations for Patients

Based on this review, here is what patients should know and consider:

1. Understand the diagnostic process. An MS diagnosis is not based on any single test. It integrates neurological examination, MRI findings, and cerebrospinal fluid analysis using the McDonald criteria (2017 revision). If a doctor recommends a lumbar puncture (spinal tap), it is because the CSF analysis can provide information that MRI alone cannot.
2. Ask about both tests. If you undergo CSF analysis, ask whether the laboratory will test for oligoclonal bands and/or kappa free light chains. The κFLC index offers comparable diagnostic accuracy to OCBs, with the advantage of producing a quantitative result. Some European laboratories have already adopted κFLC testing in routine clinical practice.
3. Know what a negative result means. A negative OCB or κFLC result does not rule out MS. If your symptoms and MRI are strongly suggestive of MS, your doctor may still diagnose you based on the McDonald criteria.
4. Use the early-treatment window. The evidence strongly supports early therapeutic intervention to delay long-term disease progression. If you have had a clinically isolated syndrome and tests suggest high risk of converting to MS (such as positive OCBs or an elevated κFLC index), discuss disease-modifying therapy options with your neurologist promptly.
5. Ask about your prognosis. If your CSF analysis shows IgM oligoclonal bands or an elevated IgM index, know that these have been associated with a higher risk of disease progression. This information can help you and your doctor make more informed treatment decisions.
6. If you are in follow-up, keep your testing consistent. If your κFLC levels are being monitored over time, it is best to have the measurements performed with the same assay method each time, so that changes reflect your disease status rather than laboratory variability.
7. Discuss emerging biomarkers with your doctor. The field is moving quickly. This review describes new promising biomarkers currently under investigation that could contribute to better diagnosis and monitoring of treatment response. These are not yet ready for routine clinical use, but participating in clinical registries or trials may give you access to the most current testing approaches.

For patients navigating a possible MS diagnosis, the take-home message is encouraging: diagnostic tools have improved substantially, and the newest biomarker (κFLC) offers accuracy on par with the long-standing gold standard while being faster, more objective, and easier to standardize. This progress means earlier diagnosis, better prediction of disease activity, and more informed treatment decisions—all of which translate into better long-term outcomes for people living with MS.

Frequently Asked Questions

How is multiple sclerosis actually diagnosed?

An MS diagnosis is not based on any single test. It integrates neurological examination, MRI findings, and cerebrospinal fluid analysis using the McDonald criteria, revised in 2017. Doctors must show damage to the central nervous system, lesions in multiple regions, and/or spread over time. Oligoclonal bands in cerebrospinal fluid can replace the requirement to demonstrate spread over time.

What are oligoclonal bands and why are they tested?

Oligoclonal bands are proteins produced when the immune system is active inside the brain and spinal cord. They are detected by isoelectric focusing with immunoblotting or immunofixation, considered the gold standard for showing increased IgG production in the central nervous system. The assay detects them in about 95% of patients with confirmed MS, but they can also appear in other inflammatory central nervous system diseases.

What is the kappa free light chain test and how accurate is it?

Kappa free light chains are light chains made in excess by B cells. The kappa free light chain index adjusts cerebrospinal fluid levels for blood–brain barrier permeability. A recent meta-analysis found its weighted average sensitivity was 88% and specificity 89%, compared with 85% and 92% for oligoclonal bands. No difference was observed for overall diagnostic accuracy between the two tests.

Does a negative oligoclonal band or kappa free light chain result rule out MS?

No. A negative oligoclonal band or kappa free light chain result does not rule out MS. If your symptoms and MRI are strongly suggestive of MS, your doctor may still diagnose you based on the McDonald criteria. These tests are not perfect, and results must always be evaluated together with the clinical picture and other disease features.

Can the kappa free light chain index predict how active my MS will become?

Recent studies indicate the kappa free light chain index has value not only for diagnosis but also for predicting early disease activity after a first episode. Patients with higher intrathecal kappa free light chain synthesis at the time of a clinically isolated syndrome may be at greater risk of converting to clinically definite MS. Its role in long-term disability is still being defined.

What does it mean if my cerebrospinal fluid shows IgM oligoclonal bands or an elevated IgM index?

IgM oligoclonal bands can be detected as evidence of intrathecal IgM production, and their presence has been linked to an increased risk of disease progression. Likewise, the IgM index predicts a poorer disease prognosis. If your cerebrospinal fluid analysis shows these findings, this information can help you and your doctor make more informed treatment decisions.

If I am being monitored over time, does it matter which test method is used?

Yes. There is no universally standardized method for measuring kappa free light chains, and different assays and instruments produce somewhat different results. If your levels are being monitored over time, it is preferable to have measurements performed with the same assay method each time, so that changes reflect your disease status rather than laboratory variability.

I've had a clinically isolated syndrome and my spinal tap was negative for oligoclonal bands — should I get a second opinion before accepting an MS diagnosis?

A negative oligoclonal band result does not rule out MS. If symptoms and MRI strongly suggest MS, diagnosis can still be made using the 2017 McDonald criteria. The kappa free light chain index offers comparable diagnostic accuracy to oligoclonal bands and is quantitative, so some patients with a demyelinating event but no clear IgG bands may be diagnosed earlier through kappa free light chain testing. A second opinion can review whether both tests were considered. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

This patient-friendly article is based on the following peer-reviewed scientific review:

• Original title: "Multiple Sclerosis: From the Application of Oligoclonal Bands to Novel Potential Biomarkers"
• Authors: Grazia Maglio, Marina D'Agostino, Francesco Pio Caronte, Luciano Pezone, Amelia Casamassimi, Monica Rienzo, Erika Di Zazzo, Carmela Nappo, Nicola Medici, Anna Maria Molinari, and Ciro Abbondanza
• Journal: International Journal of Molecular Sciences, Volume 25, 2024, Article 5412
• Digital Object Identifier (DOI): 10.3390/ijms25105412
• Publication dates: Received April 10, 2024; Revised May 10, 2024; Accepted May 14, 2024; Published May 15, 2024
• Affiliations: University of Campania "Luigi Vanvitelli," Naples, Italy; University of Molise, Campobasso, Italy

The original review was based on a literature search of the PubMed database conducted in January 2024 using the keywords "multiple sclerosis," "detection methods," "oligoclonal bands," "kappa free light chains," "diagnosis," "prognosis," and "novel biomarkers." Of the publications identified, 93 (60 original articles and 33 literature reviews) were included in the manuscript. This patient-friendly article reflects the content of the review sections provided and summarizes the main findings for a general audience.

Note: This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your physician or neurologist with any questions you may have regarding your medical condition.